Statins: Health-promoting agents show promise for breast cancer prevention

Clinical Breast Cancer

Volumn 6, Issue 5, 2005, Pages 455-459

  Kumar, Anjali S ^a   Esserman, Laura J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A.; Estrogen receptor; Tumor development

Indexed keywords

AROMATASE; CASPASE 3; CASPASE 9; CERIVASTATIN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR 1B; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTRADIOL 17BETA DEHYDROGENASE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; MEVINOLIN; PRAVASTATIN; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P27; RAS PROTEIN; RETINOBLASTOMA PROTEIN; RHO FACTOR; RHO KINASE; SIMVASTATIN;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BREAST CANCER; CANCER INCIDENCE; CANCER INHIBITION; CANCER INVASION; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; META ANALYSIS; NONHUMAN; NOTE; RISK REDUCTION; SYSTEMATIC REVIEW;

EID: 30544451771     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2005.n.051     Document Type: Note

References (26)

1. Ernster V, Barclay J, Kerlikowske K, et al. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 1996; 275:913-918.
2. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90:1371-1388.
3. Collins R, Peto R, Armitage J. The MRC/BHF Heart Protection Study: preliminary results. Int J Clin Pract 2002; 56:53-56.
4. Amin-Hanjani S, Stagliano NE, Yamada M, et al. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke 2001; 32:980-986.
5. Wassmann S, Laufs U, Baumer AT, et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension 2001; 37:1450-1457.
6. Takemoto M, Sun J, Hiroki J, et al. Rho-kinase mediates hypoxia-induced downregulation of endothelial nitric oxide synthase. Circulation 2002; 106:57-62.
7. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997; 89:1260-1270.
8. Thunyakitpisal PD, Chaisuparat R. Simvastatin, an HMG-CoA reductase inhibitor, reduced the expression of matrix metalloproteinase-9 (Gelatinase B) in osteoblastic cells and HT1080 fibrosarcoma cells. J Pharmacol Sci 2004; 94:403-409.
9. Cauley JA, Lucas FL, Kuller LH, et al. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1999; 130:270-277.
10. Denoyelle C, Albanese P, Uzan G, et al. Molecular mechanism of the anticancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells. Cell Signal 2003; 15:327-338.
11. Esserman LJ, Campbell MJ, Shoemaker M, et al. Breast cancer inhibition by statins. Proc Am Soc Clin Oncol 2004; 23:97 (Abstract #1003).
12. Kochhar R, Khurana V, Bejjanki H, et al. Statins to reduce breast cancer risk: A case control study in U.S. female veterans. Presented at: 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, FL. Abstract #514.
13. Boudreau DM, Gardner JS, Malone KE, et al. The association between 3-hydroxy-3-methylglutanyl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women. Cancer 2004; 100:2308-2316.
14. Cauley J, Zmuda J, Lui LY, et al. Lipid-lowering drug use and breast cancer in older women: a prospective study. J Womens Health (Larchmt) 2003; 12:749-756.
15. Mortimer J, Axelrod R, Zimbro K. Effect of statins on breast cancer incidence: findings from the Sentara Health Plan. Proc Am Soc Clin Oncol 2003; 22:93 (Abstract #373).
16. Blais L, Desgagne A, LeLorier J. 3-Hydroxyl-3-methylglutaryl coenzyme A inhibitors and the risk of cancer: a nester case-control study. Arch Intern Med 2000; 160:2363-2368.
17. Beck P, Wysowski DK, Downey W, et al. Statin use and the risk of breast cancer. J Clin Epidemiol 2003; 56:280-285.
18. Kaye JA, Meier CR, Walker AM, et al. Statin use, hyperlipidemia, and the risk of breast cancer. Br J Cancer 2002; 86:1436-1439.
19. Coogan PF, Rosenberg L, Palmer JR, et al. Statin use and the risk of breast and prostate cancer. Epidemiology 2002; 13:262-267.
20. Olsen JH, Johansen C, Sorensen HT, et al. Lipid-lowering medication and risk of cancer. J Clin Epidemiol 1999; 52:167-169.
21. Singal R, Khurana G, Caldito C, et al. Statins and prostate cancer risk: A large case control study in veterans. Presented at: 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, FL. Abstract #1004.
22. Khurana V, Kochhar R, Bejjanki HR, et al. Statins reduce the incidence of lung cancer: a study of half a million U.S. veterans. Presented at: the 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, FL. Abstract #1006.
23. Kumar AS, Minami C, Shim V, et al. Statin-using breast cancer patients are less likely to have ER-negative tumors. Presented at: 28th Annual San Antonio Breast Cancer Symposium; December 8-11, 2005; San Antonio, TX.
24. Pedersen TR, Wilhelmsen L, Faergeman O, et al. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am J Cardiol 2000; 86:257-262.
25. Hebert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278:313-321.
26. Bjerre LM, LeLorier J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med 2001; 110:716-723.